PARV4 prevalence, phylogeny, immunology and coinfection with HIV, HBV and HCV in a multicentre African cohort

Background: The seroprevalence of human parvovirus-4 (PARV4) varies considerably by region. In sub-Saharan Africa, seroprevalence is high in the general population, but little is known about the transmission routes or the prevalence of coinfection with blood-borne viruses, HBV, HCV and HIV. Methods: To further explore the characteristics of PARV4 in this setting, with a particular focus on the prevalence and significance of coinfection, we screened a cohort of 695 individuals recruited from Durban and Kimberley (South Africa) and Gaborone (Botswana) for PARV4 IgG and DNA, as well as documenting HIV, HBV and HCV status. Results: Within these cohorts, 69% of subjects were HIV-positive. We identified no cases of HCV by PCR, but 7.4% were positive for HBsAg. PARV4 IgG was positive in 42%; seroprevalence was higher in adults (69%) compared to children (21%) (p<0.0001) and in HIV-positive (52%) compared to HIV-negative individuals (24%) (p<0.0001), but there was no association with HBsAg status. We developed an on-line tool to allow visualization of coinfection data ( https://purl.oclc.org/coinfection-viz). We identified five subjects who were PCR-positive for PARV4 genotype-3. Ex vivo CD8+ T cell responses spanned the entire PARV4 proteome and we propose a novel HLA-B*57:03-restricted epitope within the NS protein. Conclusions: This characterisation of PARV4 infection provides enhanced insights into the epidemiology of infection and co-infection in African cohorts, and provides the foundations for planning further focused studies to elucidate transmission pathways, immune responses, and the clinical significance of this organism.

[1]  P. Klenerman,et al.  Human parvovirus 4 ‘PARV4’ remains elusive despite a decade of study , 2017, F1000Research.

[2]  K. Jeffery,et al.  Screening, characterisation and prevention of Hepatitis B virus (HBV) co-infection in HIV-positive children in South Africa , 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[3]  O. Pybus,et al.  Evaluation of Viremia Frequencies of a Novel Human Pegivirus by Using Bioinformatic Screening and PCR , 2016, Emerging infectious diseases.

[4]  N. Jojic,et al.  HLA-A is a Predictor of Hepatitis B e Antigen Status in HIV-Positive African Adults , 2015, The Journal of infectious diseases.

[5]  P. Klenerman,et al.  Ongoing burden of disease and mortality from HIV/CMV coinfection in Africa in the antiretroviral therapy era , 2015, Front. Microbiol..

[6]  T. Ndung’u,et al.  Prevalence and Characteristics of Hepatitis B Virus (HBV) Coinfection among HIV-Positive Women in South Africa and Botswana , 2015, PloS one.

[7]  P. Klenerman,et al.  Human Parvovirus 4 Infection among Mothers and Children in South Africa , 2015, Emerging infectious diseases.

[8]  P. Klenerman,et al.  Epidemiology and impact of HIV coinfection with hepatitis B and hepatitis C viruses in Sub-Saharan Africa. , 2014, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[9]  R. Burnett,et al.  Evidence for a change in the epidemiology of hepatitis B virus infection after nearly two decades of universal hepatitis B vaccination in South Africa , 2014, Journal of medical virology.

[10]  P. Klenerman,et al.  PARV4: An Emerging Tetraparvovirus , 2014, PLoS pathogens.

[11]  O. Laeyendecker,et al.  High frequency of false-positive hepatitis C virus enzyme-linked immunosorbent assay in Rakai, Uganda. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  Koichiro Tamura,et al.  MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. , 2013, Molecular biology and evolution.

[13]  D. Heckerman,et al.  Nef-Specific CD8+ T Cell Responses Contribute to HIV-1 Immune Control , 2013, PloS one.

[14]  P. Klenerman,et al.  Evolution of CD8+ T Cell Responses after Acute PARV4 Infection , 2013, Journal of Virology.

[15]  D. Heckerman,et al.  Co-Operative Additive Effects between HLA Alleles in Control of HIV-1 , 2012, PloS one.

[16]  J. Drexler,et al.  Human Parvovirus 4 in Nasal and Fecal Specimens from Children, Ghana , 2012, Emerging infectious diseases.

[17]  J. Drexler,et al.  Human Parvovirus 4 Viremia in Young Children, Ghana , 2012, Emerging infectious diseases.

[18]  C. Boesch,et al.  Diversity of Parvovirus 4–like Viruses in Humans, Chimpanzees, and Monkeys in Hunter–Prey Relationships , 2012, Emerging infectious diseases.

[19]  E. Frangou,et al.  Parvovirus 4 Infection and Clinical Outcome in High-Risk Populations , 2012, The Journal of infectious diseases.

[20]  P. Simmonds SSE: a nucleotide and amino acid sequence analysis platform , 2012, BMC Research Notes.

[21]  B. Walker,et al.  HLA-B*57 Micropolymorphism Shapes HLA Allele-Specific Epitope Immunogenicity, Selection Pressure, and HIV Immune Control , 2011, Journal of Virology.

[22]  D. Heckerman,et al.  HLA-A*7401–Mediated Control of HIV Viremia Is Independent of Its Linkage Disequilibrium with HLA-B*5703 , 2011, The Journal of Immunology.

[23]  P. Klenerman,et al.  High Frequency, Sustained T Cell Responses to PARV4 Suggest Viral Persistence In Vivo , 2011, The Journal of infectious diseases.

[24]  P. Simmonds,et al.  Serodiagnosis of Primary Infections with Human Parvovirus 4, Finland , 2011, Emerging infectious diseases.

[25]  P. Ocama,et al.  Poor performance of hepatitis C antibody tests in hospital patients in Uganda , 2010, Journal of medical virology.

[26]  O. Pybus,et al.  Widespread Infection with Homologues of Human Parvoviruses B19, PARV4, and Human Bocavirus of Chimpanzees and Gorillas in the Wild , 2010, Journal of Virology.

[27]  P. Klenerman,et al.  High frequencies of exposure to the novel human parvovirus PARV4 in hemophiliacs and injection drug users, as detected by a serological assay for PARV4 antibodies. , 2009, The Journal of infectious diseases.

[28]  David Heckerman,et al.  Adaptation of HIV-1 to human leukocyte antigen class I , 2009, Nature.

[29]  P. Simmonds,et al.  A third genotype of the human parvovirus PARV4 in sub-Saharan Africa. , 2008, The Journal of general virology.

[30]  D. Heckerman,et al.  Central Role of Reverting Mutations in HLA Associations with Human Immunodeficiency Virus Set Point , 2008, Journal of Virology.

[31]  P. Simmonds,et al.  Parenteral Transmission of the Novel Human Parvovirus PARV4 , 2007, Emerging infectious diseases.

[32]  P. Simmonds,et al.  Comparison of Tissue Distribution, Persistence, and Molecular Epidemiology of Parvovirus B19 and Novel Human Parvoviruses PARV4 and Human Bocavirus , 2007, The Journal of infectious diseases.

[33]  David Heckerman,et al.  CD8+ T-cell responses to different HIV proteins have discordant associations with viral load , 2007, Nature Medicine.

[34]  P. Simmonds,et al.  New DNA Viruses Identified in Patients with Acute Viral Infection Syndrome , 2005, Journal of Virology.

[35]  M. Bunce PCR-sequence-specific primer typing of HLA class I and class II alleles. , 2003, Methods in molecular biology.

[36]  S. Louw,et al.  High prevalence of GBV‐C hepatitis G virus infection in a rural South African population , 1997, Journal of medical virology.